title: [Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells].
abstract: OBJECTIVE
  Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance significantly limits its use in clinical practice. Study found that TRIM24 was overexpressed in non-small cell lung cancer (NSCLC) tissues and regulate cell growth, cell cycle and apoptosis in lung cell lines. The aim of this study is to explore the mechanism of TRIM24 to regulate resistance of Gefitinib in NSCLC cells.
  
  
  METHODS
  MTT and apoptosis were used to detect the change of cell grow and cell apoptosis with down-expression TRIM24 and ShTRIM24 with presence of Gefitinib. Meanwhile, Western blot was used to detect the expression of protein related to apoptosis and AKT signal path.
  
  
  RESULTS
  TRIM24 interference could improve the effect of gefitinib on cell growth inhibition and upregulate the cell apoptosis in A549 cell. Down-regulated of endogenous TRIM24 and ShTRIM24 with Gifitinib could also reduce the protein related apoptosis, such as p-BAD and Bcl-2, and the protein PIK3CA related AKT signal path in A549 cell.
  
  
  CONCLUSIONS
  TRIM24 could regulate required resistance to Gefitinib via Akt pathway in NSCLC.
authors.affiliation: Department of Pathology, College of Basic Medical Science, Xuzhou Medical College, Xuzhou 221000, China.
authors.forename: Haiying
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Pathology, College of Basic Medical Science, Xuzhou Medical College, Xuzhou 221000, China.
authors.forename: Qingling
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Pathology, College of Basic Medical Science, Xuzhou Medical College, Xuzhou 221000, China.
authors.forename: Haijun
authors.initials: H
authors.lastname: Bao
authors.affiliation: Department of Pathology, College of Basic Medical Science, Xuzhou Medical College, Xuzhou 221000, China.
authors.forename: Heng
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Pathology, College of Basic Medical Science, Xuzhou Medical College, Xuzhou 221000, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhuang
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D011799:Quinazolines / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D002352:Carrier Proteins; D011799:Quinazolines; C555317:TRIM24 protein, human; D051057:Proto-Oncogene Proteins c-akt; D000077156:Gefitinib